Monday, 23 February 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 23 February 2026
News

Ban hits fake weight loss drugs

Posted 22 May 2024 PM

The Federal Government will ban "dangerous" compounded replicas of blockbuster weight loss drugs Novo Nordisk's Ozempic and Lilly's Mounjaro from October on the advice of the TGA, insisting it will save lives.

Under new regulations, pharmacists and other healthcare practitioners will no longer be allowed to compound GLP-1 RAs. It follows a growing number of reports of  harm to patients using the fake products, including one hospitalisation in Australia due to a serious adverse event.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (11)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (5)

Other (16)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.